Neonatal CD19+B220lo cells sense microbiota via TLR2/4 activation driving proliferation and differentiation
Clinical Scorecard: Neonatal CD19+B220lo B Cells Respond to Microbiota Through TLR2/4 Activation, Promoting Their Proliferation and Differentiation
At a Glance
Category Detail
Condition Neonatal respiratory infections Key Mechanisms Activation of CD19+B220lo B cells via TLR2 and TLR4 leading to proliferation and differentiation. Target Population Neonates Care Setting Neonatal intensive care and immunology research
Key Highlights
CD19+B220lo B cells in neonatal lungs respond to microbiota through TLR2/4 activation. In vitro stimulation with TLR ligands induces proliferation and differentiation of these B cells. Higher frequency of CD138+ cells observed in CD19+B220lo populations post TLR stimulation. Lung cultures exhibit an inflammatory cytokine profile, contrasting with the regulatory profile in spleen cultures. Antibiotic treatment alters the number and immunoglobulin repertoire of neonatal B cells. Guideline-Based Recommendations
Diagnosis
Assess B cell populations in neonatal respiratory infections. Management
Consider the role of microbiota in neonatal immune responses. Monitoring & Follow-up
Monitor cytokine profiles in lung and spleen cultures. Risks
Antibiotic treatment may reduce beneficial B cell populations. Patient & Prescribing Data
Neonates at risk of respiratory infections.
Understanding TLR pathways may inform therapeutic strategies.
Clinical Best Practices
Evaluate the impact of microbiota on neonatal immune development. Utilize TLR ligands in research to study B cell activation. Related Resources & Content
